AHEAD A3 (NCT04468659) lecanemab preclinical-AD trial protocol mandates APOE genotyping and stratified arm allocation; eligibility design directly references prior anti-Aβ MAb ARIA-E APOE4-dose-dependence including bapineuzumab 302.

Evidence span

AHEAD A3 (NCT04468659) lecanemab preclinical-AD trial protocol mandates APOE genotyping and stratified arm allocation; eligibility design directly references prior anti-Aβ MAb ARIA-E APOE4-dose-dependence including bapineuzumab 302.

Method & conditions

Evidence type

observational

Method

manual state transition

Species

Homo sapiens

Conditions

Eisai/ACTC AHEAD A3 protocol amendment 2022.

Replicated

not yet

Confidence basis

operator-supplied frontier prior; review required